pJAK2(1001-1013)
Based on 1 Customer Validation
pJAK2(1001-1013) is a cell-penetrating peptide that corresponds to the activation loop of JAK2 tyrosine kinase and functions as a SOCS1/3antagonist. pJAK2 (1001-1013) blocks SOCS1-mediated negative regulation of immune function, and enhances the biological activity of cytokines such as IFNγ and IL6. pJAK2(1001-1013) inhibits the replication of a broad range of viruses and exerts dose-dependent protective efficacy against lethal viral infections. pJAK2(1001-1013) can be used for the study of immune regulation and infection.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.89%
- CAS. Nr.: 1259928-08-9
- Formel: C76H118N17O26P
- Molecular Weight:1716.82
-
Speicherung:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
pJAK2 (1001-1013) (50 μM) inhibits vaccinia virus replication by approximately 92% (intracellular virus yield) and 83% (extracellular virus yield)[1].
pJAK2 (1001-1013) (24 μM) inhibits EMCV growth by approximately 50%[1].
pJAK2(1001-1013) (11 μM, 22 h pretreatment) enhances the antiviral activity of suboptimal IFN-γ against encephalomyocarditis virus (EMCV) in human fibroblast WISH cells[2].
pJAK2(1001-1013) (20 μM, 30 min treatment) reverses SOCS-1-induced inhibition of IL-6-mediated STAT3 phosphorylation in SOCS-1-transfected human prostate cancer LNCaP cells[2].
pJAK2(1001-1013) (1-5 μM, 48 h) enhances IFN-γ-induced GAS promoter activity in WISH cells (transfected with pGAS-Luc reporter plasmid)[2].
pJAK2(1001-1013) (18 h pretreatment) inhibits replication of influenza A virus PR8 strain in MDCK cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
pJAK2(1001–1013) (200 μg/mouse, i.p., on day -2, -1, and 0 relative to BSA immunization) enhances the Ag-specific immune response in C57BL/6 mice[2].
pJAK2(1001-1013) (200 μg/mouse, i.p., once daily for 1 week) demonstrates protective efficacy against lethal infection with influenza A/PR8 virus in female C57BL/6 mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 mice were intranasally challenged with a lethal dose of vaccinia virus or infected with encephalomyocarditis virus (EMCV) to establish a viral infection model[1]
-
Dosage:10 μg, 50 μg, 200 μg
-
Administration:i.p., on days -2, -1, and 0 relative to virus challenge, once per day or every other day starting from day 2 post-virus infection
-
Result:Achieved dose-dependent protective efficacy.
-
Animal Model:C57BL/6 mice (used for Ag-specific immune response evaluation) were intraperitoneally injected with 50 μg bovine serum albumin (BSA) to establish an Ag-specific immune model[2]
-
Dosage:200 μg/mouse
-
Administration:i.p., on day -2, -1, and 0 relative to BSA immunization
-
Result:Enhanced Ag-specific splenocyte proliferation 4 weeks post-BSA injection.
-
Animal Model:Mouse-adapted influenza A/PR8 virus (10×LD50 pfu in 10 μL PBS) was intranasally administered to 6-8-week-old female C57BL/6 mice, with 5 μL delivered into each nostril of lightly anesthetized mice[3]
-
Dosage:200 μg/mouse
-
Administration:i.p., once daily for 1 week
-
Result:Demonstrated protective efficacy against lethal infection with influenza A/PR8 virus.
Alleviated influenza A/PR8 virus-induced morbidity in female C57BL/6 mice.
Chemical Information
-
CAS. Nr. 1259928-08-9
-
Appearance Solid
-
Molecular Weight 1716.82
-
Formel C76H118N17O26P
-
Color White to off-white
-
Sequence
Leu-Pro-Gln-Asp-Lys-Glu-{pTyr}-Tyr-Lys-Val-Lys-Glu-Pro
-
Sequence Shortening
LPQDKE-{pTyr}-YKVKEP
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Lösungsmittel & Löslichkeit
DMSO : 1.89 mg/mL (1.10 mM; ultrasonic and adjust pH to 2 with 1 M HCl; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 15% Cremophor EL 85% Saline
Solubility: 10 mg/mL (5.82 mM); Clear solution; Need ultrasonic
Reinheit & Dokumentation
-
Data Sheet (283 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Ahmed CM, et al. SOCS1 Mimetics and Antagonists: A Complementary Approach to Positive and Negative Regulation of Immune Function. Front Immunol. 2015 Apr 21;6:183. [Content Brief]
[2]. Waiboci LW, et al. Both the suppressor of cytokine signaling 1 (SOCS-1) kinase inhibitory region and SOCS-1 mimetic bind to JAK2 autophosphorylation site: implications for the development of a SOCS-1 antagonist. J Immunol. 2007 Apr 15;178(8):5058-68. [Content Brief]
[3]. Ahmed CM, et al. A SOCS1/3 Antagonist Peptide Protects Mice Against Lethal Infection with Influenza A Virus. Front Immunol. 2015 Nov 11;6:574. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.5825 mL | 2.9124 mL | 5.8247 mL | 14.5618 mL |
pJAK2(1001-1013) Related Classifications
HY-P10373 Related Classifications
Powered by Bioz